Evolent Health, Inc.EVHNYSE
Loading
Operating Cash Flow Growth Recovery in ProgressRecovering
Percentile Rank82
3Y CAGR-43.0%
5Y CAGR+41.1%
Year-over-Year Change
Year-over-year operating cash flow growth rate
3Y CAGR
-43.0%/yr
Quarterly compound
5Y CAGR
+41.1%/yr
Recent deceleration
Percentile
P82
Within normal range
vs 5Y Ago
5.6x
Strong expansion
Streak
2 qtr
Consecutive growthRecovering
| Period | Value |
|---|---|
| Q4 2025 | 208.63% |
| Q3 2025 | 152.13% |
| Q2 2025 | -764.49% |
| Q1 2025 | 117.40% |
| Q4 2024 | -240.50% |
| Q3 2024 | -12.83% |
| Q2 2024 | 336.28% |
| Q1 2024 | -94.51% |
| Q4 2023 | 47.69% |
| Q3 2023 | 9153.98% |
| Q2 2023 | 108.20% |
| Q1 2023 | -122.34% |
| Q4 2022 | 1128.67% |
| Q3 2022 | -125.40% |
| Q2 2022 | 123.79% |
| Q1 2022 | -186.18% |
| Q4 2021 | 49.79% |
| Q3 2021 | 283.53% |
| Q2 2021 | 49.66% |
| Q1 2021 | -274.78% |
| Q4 2020 | 37.31% |
| Q3 2020 | -154.42% |
| Q2 2020 | 283.37% |
| Q1 2020 | -255.77% |
| Q4 2019 | 179.49% |
| Q3 2019 | -22.59% |
| Q2 2019 | 47.36% |
| Q1 2019 | -2.97% |
| Q4 2018 | -211.86% |
| Q3 2018 | 233.10% |
| Q2 2018 | 127.12% |
| Q1 2018 | -350.48% |
| Q4 2017 | -7.99% |
| Q3 2017 | 207.76% |
| Q2 2017 | 71.39% |
| Q1 2017 | -61.66% |
| Q4 2016 | -371.77% |
| Q3 2016 | 325.44% |
| Q2 2016 | 80.93% |
| Q1 2016 | -191.68% |